Rethinking the Immune Responses Induced by Commercial Multicomponent Acellular and Whole Cell Pertussis Vaccines and Pertussis Infection in the Baboon Model

Whooping cough, known medically as pertussis, is a highly contagious respiratory illness caused by a specific type of bacteria. While it can be mild in adults, it poses a severe threat to infants, potentially leading to pneumonia, permanent disability, or death. For decades, the primary defense against this disease has been vaccination. Historically, the first vaccines used to fight whooping cough were made from whole, killed bacteria. These "whole cell" vaccines were highly effective at preventing not just the sickness, but also the spread of the bacteria from person to person. However, they often caused significant side effects, leading to their replacement in the 1990s with "acellular" vaccines. These newer versions contain only a few purified parts of the bacteria rather than the whole organism. While the acellular vaccines are safer and still protect children from getting very sick, public health data shows a troubling trend: in countries using these newer vaccines, the number of whooping cough cases has risen steadily. Scientists have long suspected that while the newer vaccines stop the disease, they fail to stop the bacteria from living in the nose and throat and spreading to others, but the biological reasons for this difference have remained unclear.

To solve this mystery, researchers turned to a model that closely mimics human physiology: the baboon. In a comprehensive study, scientists compared the immune systems of baboons after they received the modern acellular vaccine, the older whole-cell vaccine, or after they were naturally infected with the bacteria. The goal was to look deep inside the blood cells to see how the body's defense system reacts to each of these three scenarios. The researchers did not just look for antibodies, which are the proteins that neutralize germs; they mapped the activity of thousands of genes to understand the broader conversation happening between different parts of the immune system. They wanted to see if the newer vaccine was sending a different set of instructions to the body's defenses compared to the older vaccine or a real infection.

The study revealed that the three exposures trigger fundamentally different immune landscapes. When the baboons received the modern acellular vaccine, their bodies launched a strong, rapid response that looked very much like a reaction to a virus. This was likely because the vaccine contained a component meant to protect against polio, which the immune system recognized as a viral threat. This "antiviral" signal caused the immune system to produce specific proteins designed to fight viruses and activated a type of white blood cell known as a cytotoxic T cell, which hunts down infected cells. However, this response did not include the full suite of signals needed to clear a bacterial infection from the lungs. The immune system was busy preparing for a viral battle rather than a bacterial one.

In contrast, the baboons that received the older whole-cell vaccine or those that were naturally infected with the bacteria showed a very different pattern. Their immune systems activated a pathway involving a specific type of white blood cell called a neutrophil, which is crucial for fighting bacterial invasions. This response was driven by a complex chain of signals that included inflammatory markers and a specific type of immune cell called a Th17 cell. These cells are known to be essential for clearing bacteria from the respiratory tract and preventing them from spreading. The researchers found that the whole-cell vaccine and the natural infection both successfully triggered this bacterial-fighting machinery, whereas the modern acellular vaccine largely failed to do so. This difference helps explain why the older vaccine and natural infection provide better protection against spreading the disease, even though the newer vaccine is safer and still prevents severe illness.

The study also uncovered subtle but important differences in how the body handles the vaccine ingredients. The modern acellular vaccine, which includes the polio component, seemed to keep the immune system in a more tightly regulated state. It activated genes associated with red blood cell production and blood clotting, suggesting the body was managing resources carefully without launching a full-scale inflammatory war. The older vaccine and the infection, on the other hand, triggered a more robust and broader inflammatory response. This included the activation of genes that help the immune system remember the infection for the long term, creating a more durable defense. The researchers observed that the baboons infected with the bacteria developed a strong memory of the specific germ, while those with the whole-cell vaccine showed a balanced mix of immediate defense and long-term memory. The acellular vaccine group, however, showed a strong focus on producing immediate antibodies but lacked the same depth of long-term cellular memory found in the other two groups.

One of the most striking findings was how the composition of the vaccine changed the immune response. The modern acellular vaccine used in the study was a "pentavalent" version, meaning it protected against five different diseases at once. The researchers found that the inclusion of the polio component in this mix was a major driver of the antiviral response. This suggests that the way vaccines are packaged today—combining multiple antigens into a single shot—might be shaping the immune system's reaction in ways that were not seen with older, single-disease vaccines. The study did not find that the newer vaccine was "wrong" or ineffective; rather, it showed that it teaches the immune system a different lesson. It teaches the body to make antibodies to stop the disease symptoms, but it does not teach the body to clear the bacteria from the airways or stop it from spreading.

The researchers also looked at how the immune system regulates itself to prevent overreaction. In the groups that received the whole-cell vaccine or the natural infection, the body produced signals that help calm down the immune response after the bacteria were cleared. In the acellular vaccine group, the body activated different regulatory signals, including those associated with a type of cell that suppresses immune activity. This suggests that the newer vaccine might be keeping the immune system in a state of high alert but low aggression, which is safe but perhaps less effective at clearing the bacteria. The study confirmed that while the acellular vaccine is excellent at preventing severe coughing fits and hospitalization, it does not create the same "sterilizing" immunity that stops the bacteria from taking hold in the first place.

These findings provide a clear biological explanation for the epidemiological data that has puzzled health officials for years. The shift from whole-cell to acellular vaccines has saved lives by reducing severe disease, but it has also changed the nature of the immune response in a way that allows the bacteria to persist and spread. The study suggests that the path forward for vaccine design may lie in understanding how to combine the safety of the acellular vaccine with the powerful, broad-spectrum immune activation of the whole-cell version. By using the baboon model, the researchers were able to see these complex interactions in a living system, offering a roadmap for developing the next generation of vaccines that can protect against both the disease and its spread. The work highlights that the immune system is not a single switch that can be turned on or off, but a complex network that responds differently depending on exactly what it is shown. Understanding these nuances is essential for creating vaccines that offer complete protection for everyone.